Emerging Markets Earnings: Eli Lilly Finds Room To Grow In Asia, Brazil
This article was originally published in PharmAsia News
Eli Lilly finds a bright spot in emerging markets for the third quarter with insulin a prime driver of growth.
You may also be interested in...
Timing could be right for changes to the U.S. corporate tax policy, Lilly CEO said during third quarter earning call; the problem, however, is working out the details.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.